USPH VS TARO Stock Comparison

Performance

USPH
100/100

USPH returned 2.89% in the last 12 months. Based on SPY's performance of -13.44%, its performance is above average giving it a score of 100 of 100.

TARO
100/100

TARO returned 25.59% in the last 12 months. Based on SPY's performance of -12.10%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

USPH
61/100

7 analysts offer 12-month price targets for USPH. Together, they have an average target of 0, the most optimistic target put USPH at 0 within 12-months and the most pessimistic has USPH at 0.

TARO
50/100

1 analysts offer 12-month price targets for TARO. Together, they have an average target of 0, the most optimistic target put TARO at 0 within 12-months and the most pessimistic has TARO at 0.

Sentiment

USPH
67/100

USPH had a bullish sentiment score of 66.64% across Twitter and StockTwits over the last 12 months. It had an average of 2.88 posts, 0.12 comments, and 0.00 likes per day.

TARO
87/100

TARO had a bullish sentiment score of 86.67% across Twitter and StockTwits over the last 12 months. It had an average of 1.00 posts, 0.00 comments, and 2.50 likes per day.

Technicals

USPH
50/100

USPH receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.

TARO
86/100

TARO receives a 85 of 100 based on 14 indicators. 11 are bullish, 1 are bearish.

Earnings

USPH
69/100

USPH has missed earnings 2 times in the last 20 quarters.

TARO
10/100

TARO has missed earnings 12 times in the last 20 quarters.

Profit

USPH
61/100

Out of the last 20 quarters, USPH has had 20 profitable quarters and has increased their profits year over year on 5 of them.

TARO
48/100

Out of the last 20 quarters, TARO has had 16 profitable quarters and has increased their profits year over year on 3 of them.

Volatility

USPH
55/100

USPH has had a higher than average amount of volatility over the last 12 months giving it a score of 54 of 100.

TARO
53/100

TARO has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.

Dividend

USPH
19/100

USPH's most recent dividend was $0.82 per share, based on a share price of $87.22. It was a payout ratio of 95.21% compared to their total earnings.

TARO

"Dividend" not found for TARO

All score calculations are broken down here to help you make more informed investing decisions

US Physical Therapy Inc Summary

New York Stock Exchange / USPH

Healthcare

Medical - Care Facilities

U.S. Physical Therapy, Inc., through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. It operates through two segments, Physical Therapy Operations and Industrial Injury Prevention Services. The company offers industrial injury prevention services, including onsite injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments through physical therapists and specialized certified athletic trainers for Fortune 500 companies, and other clients comprising insurers and their contractors. As of December 31, 2021, it operated 591 clinics in 39 states; and managed 35 physical therapy practice facilities. The company was founded in 1990 and is based in Houston, Texas.

Taro Pharmaceutical Industries Ltd. Summary

New York Stock Exchange / TARO

Healthcare

Drug Manufacturers - Specialty & Generic

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug store chains, food chains, hospitals, mass merchandisers, grocery chains, and other direct purchasers and customers, as well as healthcare institutions and private pharmacies. The company was founded in 1950 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.

Power up your portfolio